Amivantamab
Rybrevant · EGFR-MET bispecific antibody
Newly recognized acute interstitial nephritis in lung cancer — flagged by clinicians.
AINLYTE
ModerateOpen →
The Drug Explorer
Search the nephrotoxic landscape
A live index of 240+ anti-cancer agents, cross-filterable by injury signature, drug class, nephron segment, severity, and era. Profiled agents open to a full citation-grounded page; the rest are catalog entries with their signature kidney signal.
17 agents · filtered from 240
Profile
Atezolizumab
Tecentriq · Anti-PD-L1 antibody
Interstitial nephritis; rare glomerular disease.
AINGLOM
ModerateOpen →
Avelumab
Bavencio · Anti-PD-L1 antibody
ICI-associated AIN.
AINGLOM
ModerateOpen →
Bicalutamide
Casodex · Nonsteroidal antiandrogen
Hepatically cleared, kidney-neutral, no renal dose adjustment; only rare idiosyncratic interstitial nephritis.
AINLYTE
MildOpen →
BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib)
BRAF/MEK inhibitor
Tubulointerstitial AKI; vemurafenib strongest.
ATNAINLYTE
MildOpen →
Cemiplimab
Libtayo · Anti-PD-1 antibody
ICI-associated AIN.
AINGLOM
ModerateOpen →
Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)
Immune checkpoint inhibitor
Acute interstitial nephritis with long latency.
AIN
ModerateOpen →
Cobimetinib
Cotellic · MEK inhibitor
Real-world AKI signal with BRAF partners.
ATNAIN
MildOpen →
Dostarlimab
Jemperli · Anti-PD-1 antibody
ICI-associated AIN.
AINGLOM
ModerateOpen →
Durvalumab
Imfinzi · Anti-PD-L1 antibody
ICI-associated AIN.
AINGLOM
ModerateOpen →
Duvelisib
Copiktra · PI3Kδ/γ inhibitor
Colitis and diarrhea → prerenal AKI.
PREAIN
MildOpen →
Encorafenib
Braftovi · BRAF inhibitor
Class tubular signal; usually mild.
ATNAIN
MildOpen →
Ibrutinib
Imbruvica · BTK inhibitor
Tumor lysis, hypertension and AKI.
HTNPREGLOM
ModerateOpen →
Idelalisib
Zydelig · PI3Kδ inhibitor
Immune-mediated colitis → volume-depletion prerenal AKI; transaminitis.
PREAIN
MildOpen →
Procarbazine
Matulane · Hydrazine alkylating agent
Classic cytotoxic with recognized renal/urological complications; AKI usually multifactorial; hypersensitivity AIN possible.
ATNAIN
ModerateOpen →
Relatlimab
Opdualag · Immune checkpoint inhibitor (anti-LAG-3)
2022 LAG-3 inhibitor (with nivolumab); class immune-mediated AIN, amplified by combination ICI.
AIN
ModerateOpen →
Sacituzumab govitecan
Trodelvy · Antibody-drug conjugate (Trop-2/SN-38)
Diarrhea-driven prerenal AKI; emerging direct signals.
PREAINATN
ModerateOpen →